Total item
Cart Subtotal
$0.00 - Y Kaibori, .et al. EphA2 phosphorylation at Ser897 by the Cdk1/MEK/ERK/RSK pathway regulates M-phase progression via maintenance of cortical rigidity, the FASEB Journal, 2019, Jan 22:fj201801519RR PMID: 30668924
Biological Activity
NVP-BHG712 is a selective inhibitor of EphB4 kinase that exhibits selectivity for EphB4 over more than 40 other kinases in vitro, including FGFR3.
Targets
| Target | Value | |
|---|---|---|
| EphB4 | ED50 | 25nM |
| C-Raf | IC50: 0.395μM | |
| c-Src | IC50: 1.266μM | |
| c-Abl | IC50: 1.667μM | |
| Tie-2 | IC50: >10μM | |
| Axl | IC50: >10μM | |
| HER1 | IC50: >10μM | |
| PKA | IC50: >10μM | |
| CDK1 | IC50: >10μM | |
| PKB | IC50: >10μM | |
| PDK-1 | IC50: >10μM | |
| FGFR3 | IC50: >10μM | |
| c-Met | IC50: >10μM |
| In vitro (25°C) | DMSO | 101 mg/mL (200.6 mM) | |
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | 3 mg/mL (5.95 mM) | ||
| In vivo | NMP/polyethylene glycol 300 (10/90, v/v) | 30 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 19.86 mL | 99.3 mL | 198.61 mL |
| 0.5 mM | 3.97 mL | 19.86 mL | 39.72 mL |
| 1 mM | 1.99 mL | 9.93 mL | 19.86 mL |
| 5 mM | 0.4 mL | 1.99 mL | 3.97 mL |
*The above data is based on the productmolecular weight 503.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A10661 |
|---|---|
| Actions | Inhibitor |
| M. Wt | 503.5 |
| Formula | C26H20F3N7O |
| Solubility | DMSO |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 940310-85-0 |
| Synonyms | NVPBHG712 |
| SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)NC3=NC(=NC4=C3C=NN4C)C5=CN=CC=C5 |
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
Regorafenib (BAY 73-4506)
Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an ora…
TAK-632
TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50, 2.4 nM; BRAF(wt), 8.3 nM; CRAF, 1.4 nM; pMEK (A3…
Dabigatran ethyl ester
Dabigatran ethyl ester, which is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
ZM 336372
ZM 336372 is a potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activatio…
LGX 818 (Encorafenib)
LGX818 is an orally available Raf kinase inhibitor with potential antineoplastic activity.
AZ628
AZ628 is a RAF inhibitor with IC50 values: ca 30 nM for BRAF V600E and wild-type CRAF and 100 nM for wild-type BRAF.
B-Raf-inhibitor 1
B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 uM and 2 nM for A375 proliferation and A375 p-ERK respec…
HG6-64-1
HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.
Keywords:buy NVP-BHG712 | NVP-BHG712 Supplier | purchase | cost | manufacturer | order | distributor | buy 940310-85-0| 940310-85-0 Supplier | purchase 940310-85-0 | 940310-85-0 cost | 940310-85-0 manufacturer | order 940310-85-0 | 940310-85-0 distributor
Adooq Quality Guarantee
We promise all products perform as described.